Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

UNLABELLED: PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like. METHODS A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen. RESULTS: The intrinsic subtypes as discrete entities showed prognostic significance (P…

• SG
  Susan G. Komen for the Cure
• BC
  Breast Cancer Research Foundation
• HC
  Huntsman Cancer Institute

  Award: P30 CA42014
• AI
  ARUP Institute for Clinical and Experimental Pathology
• AJ
  Alvin J. Siteman Cancer Center

  Awards: CA91842, P30 CA91842
• NC
  National Cancer Institute

  Awards: P30 CA42014, P50-CA58223, CA42014, U01 CA114722-01, P50-CA58223-09A1, CA58223, P30 CA91842, CA91842